CD44 and ovarian cancer: DLX4, therefore, might contribute to poor outcomes in ovarian cancer, in part, by promoting peritoneal implantation of tumor cells via enhanced CD44 expression and tumor-mesothelial cell interactions in an NF-κB-dependent manner.